Hiroyuki Okuzawa
CEO & Representative Director
oncology strategypharmaceutical commercializationADC development
Details
- ●Modalities: antibody-drug conjugates, small molecules, antibodies
- ●Therapeutic areas: oncology, cardiovascular, rare diseases
- ●Key targets: HER2, HER3, TROP2, B7-H3, CDH6
- ●Indications: HER2+ breast cancer, HER2-low breast cancer, non-small cell lung cancer, colorectal cancer
- ●Funding: N/A (public, Tokyo Stock Exchange: 4568, ~¥1.6T revenue FY2024)
Partners & investors
- Public (TSE: 4568, OTC: DSNKY)· Investor
- AstraZeneca (ADC co-development partner)· Investor
Key considerations
- ●AI tools in use: DXd-ADC proprietary linker-payload platform, Computational antibody engineering, AI-assisted clinical trial optimization
- ●DXd platform enables rapid generation of new ADC candidates with optimized drug-antibody ratios
- ●Partnership with AstraZeneca (co-development of Enhertu and 3 other ADCs)
- ●Five ADC launches planned in 2026 — unprecedented for the modality
Pipeline
- Phase 34
- Approved1
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Ken Keller
President, US Operations
oncology commercial launchmarket accessUS operations